Iloprost for the treatment of bone marrow edema in the hindfoot.
The parenteral application of the vasoactive drug, iloprost, might be a viable option for the treatment of BMES of different origins, especially ischemic ones. In edema that is secondary to osteoarthrosis or stress, the effect of therapy with iloprost depends on the grade of the basic disease. The natural course of the disease, as well as the normalization of the signal pattern of the MRI, seem to be accelerated.
Aigner
N
N
First General Orthopaedic Department, Orthopaedic Hospital Vienna--Speising, Speisingerstr. 109, A-1134 Vienna, Austria. nicolas.aigner@oss.at
Meizer
R
R
Stolz
G
G
Petje
G
G
Krasny
C
C
Landsiedl
F
F
Steinboeck
G
G
D000328:Adult; D000368:Aged; D001855:Bone Marrow Diseases / Q000175:diagnosis / Q000188:drug therapy* / Q000209:etiology; D004487:Edema / Q000175:diagnosis / Q000188:drug therapy* / Q000209:etiology; D005260:Female; D005534:Foot Diseases / Q000175:diagnosis / Q000188:drug therapy* / Q000209:etiology; D006801:Humans; D016285:Iloprost / Q000627:therapeutic use*; D007262:Infusions, Intravenous; D008279:Magnetic Resonance Imaging; D008297:Male; D008875:Middle Aged; D010865:Pilot Projects; D011446:Prospective Studies; D014665:Vasodilator Agents / Q000627:therapeutic use*
D014665:Vasodilator Agents; D016285:Iloprost